The iconic rise of Viagra has long been a benchmark of pharmaceutical success, yet its position within the broader market now presents questions about future returns . Copycat versions are undercutting patent protection , causing worries that investing in companies heavily reliant to Viagra's former position could be a speculative strategy, especia